Clinical Trial Will Test Whether Semaglutide Can Help People Stay Off Opioids
A Phase II randomized clinical trial will test whether adding semaglutide to standard opioid addiction treatment can increase abstinence and reduce cravings in 200 patients with treatment-resistant opioid use disorder.
Quick Facts
What This Study Found
This is a clinical trial protocol — no results are reported yet. The study design is:
- Phase II randomized, double-blind, placebo-controlled trial
- 200 participants with treatment-refractory OUD (100 on buprenorphine, 100 on methadone)
- Intervention: semaglutide (GLP-1 RA) vs. placebo added to existing MOUD
- Primary outcomes: probability of opioid abstinence, craving measures, days of drug use
- Assessment: urine toxicology screens and self-report across 19 weeks (12 treatment weeks + washout + follow-up)
- Registered: ClinicalTrials.gov NCT06548490
Key Numbers
How They Did This
Randomized, double-blind, placebo-controlled clinical trial. Participants are 200 adults enrolled in outpatient medication for opioid use disorder (MOUD) programs — split evenly between buprenorphine and methadone patients. After screening (week 1), participants receive 12 weeks of semaglutide or placebo (weeks 2-13), followed by a washout visit (week 14) and final follow-up (week 19). Outcomes assessed via urine drug screens and self-report measures.
Why This Research Matters
The opioid crisis has killed hundreds of thousands of people, and existing treatments for opioid addiction — while helpful — have high relapse rates, especially in treatment-resistant cases. If semaglutide can reduce opioid cravings through GLP-1 receptor pathways in the brain's reward system, it would represent an entirely new class of addiction medication — one that doesn't act on opioid receptors and could complement existing treatments.
The Bigger Picture
The potential of GLP-1 drugs for addiction is one of the most exciting emerging areas in neuropharmacology. GLP-1 receptors are expressed in brain reward circuits, and animal studies have shown that GLP-1 agonists reduce consumption of alcohol, nicotine, and opioids. Epidemiological data from patients taking GLP-1 drugs for diabetes have also suggested lower rates of substance use. This trial represents the critical step of rigorous human testing of this hypothesis.
What This Study Doesn't Tell Us
This is a protocol paper — no results are available. The study is Phase II with 200 participants, which may not be large enough to detect modest effect sizes. The 12-week treatment duration is relatively short for evaluating sustained abstinence. The preprint (Research Square) has not been peer-reviewed. Generalizability may be limited to outpatient MOUD populations.
Questions This Raises
- ?Does semaglutide reduce opioid cravings through the same brain reward pathways that mediate its effects on food intake?
- ?Will the anti-craving effects persist during the washout period after semaglutide is discontinued?
- ?Could GLP-1 drugs eventually become a standard add-on to methadone or buprenorphine programs for treatment-resistant patients?
Trust & Context
- Key Stat:
- 200-patient Phase II RCT First randomized, placebo-controlled trial testing semaglutide for opioid abstinence in outpatient addiction treatment patients
- Evidence Grade:
- This is a clinical trial protocol — it describes the study design but reports no results. The trial design (randomized, double-blind, placebo-controlled) is rigorous, and results when published will provide strong evidence.
- Study Age:
- Published as a preprint in 2025, with the trial registered in August 2024. Results are expected after the trial completes enrollment and follow-up.
- Original Title:
- Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.
- Published In:
- Research square (2025)
- Authors:
- Freet, Christopher S, Shuler, Kirsten, Kawasaki, Sarah, Weintraub, Eric, Greenblatt, Aaron, Kladney, Mat, Nunes, Edward, Foster, Katrina L, Kong, Lan, Raja-Khan, Nazia, Cleveland, H Harrington, Grigson, Patricia S, Bunce, Scott C, Brick, Timothy R, Nyland, Jennifer E
- Database ID:
- RPEP-10979
Evidence Hierarchy
Frequently Asked Questions
Why might a weight loss drug help with opioid addiction?
GLP-1 receptors are found not only in the gut and pancreas but also in brain areas that control reward and motivation. Just as semaglutide reduces cravings for food, it may also reduce cravings for drugs by modulating the same reward circuits. Animal studies and observational data in humans have suggested that GLP-1 drugs reduce interest in addictive substances including alcohol, nicotine, and opioids.
What does 'treatment-refractory' opioid use disorder mean?
It means patients who are already receiving standard addiction medications (buprenorphine/Suboxone or methadone) but are still using illicit opioids. These are the hardest-to-treat patients, and new approaches are desperately needed. This trial specifically targets this population to see if adding semaglutide to their existing treatment can help them achieve and maintain abstinence.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-10979APA
Freet, Christopher S; Shuler, Kirsten; Kawasaki, Sarah; Weintraub, Eric; Greenblatt, Aaron; Kladney, Mat; Nunes, Edward; Foster, Katrina L; Kong, Lan; Raja-Khan, Nazia; Cleveland, H Harrington; Grigson, Patricia S; Bunce, Scott C; Brick, Timothy R; Nyland, Jennifer E. (2025). Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.. Research square. https://doi.org/10.21203/rs.3.rs-6666196/v1
MLA
Freet, Christopher S, et al. "Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol.." Research square, 2025. https://doi.org/10.21203/rs.3.rs-6666196/v1
RethinkPeptides
RethinkPeptides Research Database. "Efficacy of the GLP-1 receptor agonist, semaglutide, in abst..." RPEP-10979. Retrieved from https://rethinkpeptides.com/research/freet-2025-efficacy-of-the-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.